Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study

Table 4 Univariate and multivariate analyses of factors influencing OS of lung cancer patients with brain metastases

Factors		Median OS, months	Univariate		Multivariate
Factors		Median OS, months	HR (95% CI)	P Value	HR (95% CI)	P Value
Age, years	< 60	15.9		0.019
Age, years	≥60	10.8	1.42 (1.06–1.91)
Sex	Male	10.0		0.016		0.002
Sex	Female	17.2	0.67 (0.48–0.93)		0.58 (0.41–0.81)
KPS	≤80	11.0		0.059
KPS	> 80	14.8	0.75 (0.56–1.01)
Number of BMs	1–3	19.5		< 0.001		< 0.001
Number of BMs	> 3	8.9	2.00 (1.48–2.71)		1.88 (1.36–2.59)
Maximum size of	< 20	11.7		0.173
BM, mm	≥20	12.9	1.22 (0.91–1.63)
Symptoms of BM	Yes	12.3		0.198
Symptoms of BM	None	12.9	0.83 (0.62–1.11)
Extracranial metastases	Yes	7.5		0.003		0.011
	None	18.3	0.68 (0.43–1.06)		0.63 (0.40–0.99)
	Unknown	15.0	0.57 (0.42–0.79)		0.61 (0.43–0.85)
Systematic Tx	CTx	14.9		< 0.001		< 0.001
Systematic Tx	No-CTx	6.0	1.83 (1.35–2.49)		2.08 (1.53–2.84)
Radiotherapy	WBRT+boost	17.9		0.002
	WBRT	8.7	1.82 (1.30–2.55)
	SRS	14.5	1.23 (0.75–2.02)

Abbreviations: OS overall survival, HR hazard ratio, CI confidence interval, KPS Karnofsky Performance Status, BM brain metastasis, CTx chemotherapy, No-CTx no chemotherapy, WBRT whole brain radiation therapy, SRS stereotactic radiosurgery, WBRT+boost whole brain radiotherapy plus focal radiation boost

ISSN: 1748-717X